EP2175023A1 — Anti-tumor activity of small double-stranded oligodeoxynucleotides targeting telomerase RNA
Assigned to Zurich Universitaet Institut fuer Medizinische Virologie · Expires 2010-04-14 · 16y expired
What this patent protects
The invention refers to an antitumor and/or anti-metastatic therapeutic, comprising siDNA oligonucleotides that bind to one or more RNA target regions of the RNA component of telomerase. The siDNA oligonucleotides comprise of one strand which is fully complementary to the templat…
USPTO Abstract
The invention refers to an antitumor and/or anti-metastatic therapeutic, comprising siDNA oligonucleotides that bind to one or more RNA target regions of the RNA component of telomerase. The siDNA oligonucleotides comprise of one strand which is fully complementary to the template region of the RNA component of Telomerase and a second strand partially complementary to the antisense strand. The siDNA oligos bind the Telomerase RNA and lead to its inactivation.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.